Search: WFRF:(van Diepen M)
> (2012-2014) >
Left Ventricular Sy...
-
McMurray, John J. V.
(author)
Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial
- Article/chapterEnglish2013
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-221705
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-221705URI
-
https://doi.org/10.1161/CIRCHEARTFAILURE.112.000143DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background-We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin. Methods and Results-The risk of a number of outcomes, including the composite of SSE or death (to take account of competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: (1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or LVSD (1.54; 5.27); each comparison P<0.0001. Each outcome was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89 (95% confidence interval, 0.81-0.98; P=0.02); for SSE, major bleed, or death it was 0.85 (0.78-0.92; P<0.001). There was no heterogeneity of treatment effect across the 3 groups. Conclusions-Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups.
Subject headings and genre
-
atrial fibrillation
-
heart failure
-
left ventricular systolic dysfunction
-
stroke
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ezekowitz, Justin A.
(author)
-
Lewis, Basil S.
(author)
-
Gersh, Bernard J.
(author)
-
van Diepen, Sean
(author)
-
Amerena, John
(author)
-
Bartunek, Jozef
(author)
-
Commerford, Patrick
(author)
-
Oh, Byung-Hee
(author)
-
Harjola, Veli-Pekka
(author)
-
Al-Khatib, Sana M.
(author)
-
Hanna, Michael
(author)
-
Alexander, John H.
(author)
-
Lopes, Renato D.
(author)
-
Wojdyla, Daniel M.
(author)
-
Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)larswall
(author)
-
Granger, Christopher B.
(author)
-
Uppsala universitetUppsala kliniska forskningscentrum (UCR)
(creator_code:org_t)
Related titles
-
In:Circulation Heart Failure6:3, s. 451-4601941-32891941-3297
Internet link
Find in a library
To the university's database
- By the author/editor
-
McMurray, John J ...
-
Ezekowitz, Justi ...
-
Lewis, Basil S.
-
Gersh, Bernard J ...
-
van Diepen, Sean
-
Amerena, John
-
show more...
-
Bartunek, Jozef
-
Commerford, Patr ...
-
Oh, Byung-Hee
-
Harjola, Veli-Pe ...
-
Al-Khatib, Sana ...
-
Hanna, Michael
-
Alexander, John ...
-
Lopes, Renato D.
-
Wojdyla, Daniel ...
-
Wallentin, Lars
-
Granger, Christo ...
-
show less...
- Articles in the publication
-
Circulation Hear ...
- By the university
-
Uppsala University